Jennifer Griffin - Amedisys Deputy VP
| AMED Stock | USD 91.15 4.86 5.06% |
Insider
Jennifer Griffin is Deputy VP of Amedisys
| Address | 3854 American Way, Baton Rouge, LA, United States, 70816 |
| Phone | 225 292 2031 |
| Web | https://www.amedisys.com |
Amedisys Management Efficiency
The company has return on total asset (ROA) of 0.0626 % which means that it generated a profit of $0.0626 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0187) %, meaning that it created substantial loss on money invested by shareholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.13, whereas Return On Tangible Assets are projected to grow to (0.01). At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 24 M, whereas Intangible Assets are forecasted to decline to about 64.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| John West | Personalis | 67 | |
| Georgeann Couchara | Danaher | 47 | |
| Alexander MD | Illumina | 47 | |
| Phil Grinnell | Natera Inc | N/A | |
| Darlene Solomon | Agilent Technologies | 65 | |
| Olesya CPA | Natera Inc | N/A | |
| Allison Ballmer | Agilent Technologies | N/A | |
| Mickey MD | Caredx Inc | N/A | |
| Mikael Dolsten | Agilent Technologies | 62 | |
| Otis Brawley | Agilent Technologies | 61 | |
| Camilla Zuckero | Castle Biosciences | N/A | |
| Erin Smith | Twist Bioscience Corp | N/A | |
| Gianluca Pettiti | Thermo Fisher Scientific | 45 | |
| Abraham Esq | Caredx Inc | 51 | |
| Kevin Haas | Myriad Genetics | 38 | |
| MD MS | Personalis | 51 | |
| RN RN | Castle Biosciences | 56 | |
| Ruby Chandy | Thermo Fisher Scientific | 58 | |
| Katharine Knobil | Agilent Technologies | 56 | |
| Kevin Pegels | Illumina | 56 | |
| Rishi Kacker | Natera Inc | N/A | |
Management Performance
| Return On Equity | -0.0187 | ||||
| Return On Asset | 0.0626 |
Amedisys Leadership Team
Elected by the shareholders, the Amedisys' board of directors comprises two types of representatives: Amedisys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amedisys. The board's role is to monitor Amedisys' management team and ensure that shareholders' interests are well served. Amedisys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amedisys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael North, Senior Vice President - Operations | ||
| John Nugent, Chief Officer | ||
| Pete Hartley, CTO Systems | ||
| Kendra Kimmons, VP Relations | ||
| Jennifer Griffin, Deputy VP | ||
| Janet Britt, VP Collections | ||
| Richard Ashworth, CEO President | ||
| Allyson Guidroz, Chief Officer | ||
| Scott Ginn, Chief Accounting Officer | ||
| Denise Bohnert, Chief Officer | ||
| Paul Kusserow, CEO and President and Director | ||
| Nick Muscato, Vice President of Strategic Finance | ||
| Adam Holton, Chief Officer |
Amedisys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amedisys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0187 | ||||
| Return On Asset | 0.0626 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 3.41 B | ||||
| Shares Outstanding | 32.68 M | ||||
| Shares Owned By Insiders | 2.30 % | ||||
| Shares Owned By Institutions | 93.33 % | ||||
| Number Of Shares Shorted | 2.21 M | ||||
| Price To Earning | 15.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share (0.64) | Revenue Per Share 69.004 | Quarterly Revenue Growth 0.027 | Return On Assets 0.0626 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.